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Oral heroin in opioid-dependent patients: Pharmacokinetic
comparison of immediate and extended release tablets
Abstract
In diacetylmorphine prescription programs for heavily dependent addicts, diacetylmorphine is usually
administered intravenously, but this may not be possible due to venosclerosis or when heroin abuse had
occurred via non-intravenous routes. Since up to 25% of patients administer diacetylmorphine orally, we
characterised morphine absorption after single oral doses of immediate and extended release
diacetylmorphine in 8 opioid addicts. Plasma concentrations were determined by liquid
chromatography-mass spectrometry. Non-compartmental methods and deconvolution were applied for
data analysis. Mean (+/-S.D.) immediate and extended release doses were 719+/-297 and 956+/-404mg,
with high absolute morphine bioavailabilities of 56-61%, respectively. Immediate release
diacetylmorphine caused rapid morphine absorption, peaking at 10-15min. Morphine absorption was
considerably slower and more sustained for extended release diacetylmorphine, with only approximately
30% of maximal immediate release absorption being reached after 10min and maintained for 3-4h, with
no relevant food interaction. The relative extended to immediate release bioavailability was calculated to
be 86% by non-compartmental analysis and 93% by deconvolution analysis. Thus, immediate and
extended release diacetylmorphine produce the intended morphine exposures. Both are suitable for
substitution treatments. Similar doses can be applied if used in combination or sequentially.
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Abstract  
In diacetylmorphine prescription programs for heavily dependent addicts, diacetylmorphine is 
usually administered intravenously, but this may not be possible due to venosclerosis or when 
heroin abuse had occurred via non-intravenous routes. Since up to 25% of patients administer 
diacetylmorphine orally, we characterised morphine absorption after single oral doses of immediate 
and extended release diacetylmorphine in 8 opioid addicts. Plasma concentrations were determined 
by liquid chromatography-mass spectrometry. Non-compartmental methods and deconvolution 
were applied for data analysis. Mean (±SD) immediate and extended release doses were 719 ± 297 
mg and 956 ± 404 mg, with high absolute morphine bioavailabilities of 56% to 61%, respectively. 
Immediate release diacetylmorphine caused rapid morphine absorption, peaking at 10 to 15 min. 
Morphine absorption was considerably slower and more sustained for extended release 
diacetylmorphine, with only ~30% of maximal immediate release absorption being reached after 10 
min and maintained for 3 to 4 h, with no relevant food interaction. The relative extended to 
immediate release bioavailability was calculated to be 86% by non-compartmental analysis and 
93% by deconvolution analysis. Thus, immediate and extended release diacetylmorphine produce 
the intended morphine exposures. Both are suitable for substitution treatments. Similar doses can be 
applied if used in combination or sequentially. 
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1. Introduction 
Opioid misuse and addiction embody a grave public health issue. Treatment in most 
countries is primarily based on methadone and buprenorphine maintenance programs (Van den 
Brink and Haasen, 2006, Amato et al., 2005). However, treatment response is often incomplete, and 
many heavily dependent narcotic addicts cannot be included or retained in these programs. 
Therefore, Switzerland and several other countries now include diacetylmorphine as an additional 
option for heavily dependent narcotic addicts (Fischer et al., 2007, van den Brink et al., 2003, 
Sheldon, 2008, Haasen et al., 2007, Brissette, 2001). Based on the three most relevant clinical 
studies in Switzerland, the Netherlands, and Germany, heroin-assisted treatment is superior to other 
opiod-assisted treatments such as methadone (Rehm et al., 2001, van den Brink et al., 2003, Haasen 
et al., 2007, Verthein et al., 2008). In particular, this treatment targets previously untreated 
intravenous drug users or non-responders to conventional methadone treatments, who subsequently 
show improvements in health status, often dramatically, less treatment dropout, reduced 
consumption of other psychotropic substances, and other social improvements. Based on these 
successful study outcomes, the Swiss and the Dutch health authorities have registered an 
intravenous diacetylmorphine formulation, and oral formulations have been submitted in 
Switzerland for marketing approval. In addition, other countries such as Spain, Belgium, Denmark, 
Canada, and the United Kingdom are planning or have already completed clinical trials with heroin-
assisted treatments. 
Treatment based solely on injected heroin as a substitution medication can be problematic. 
While effective, it requires considerable resources as patients usually inject three times a day under 
supervised conditions at treatment centres, which requires long operating hours and puts high 
demands on personnel and security. Moreover, not all patients fulfil the admission criteria; in many 
countries, a considerable fraction of opioid dependents do not inject. In the Netherlands, for 
instance, most users (i.e. 75% to 90%) inhale heroin by ‘chasing the dragon’. Also in other 
countries, many users do not inject opioids for various reasons, including fear of infection risk or 
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inability to puncture their veins. Moreover, an increasing number of patients participating in heroin-
assisted treatment programs suffer from venosclerosis, preventing them from performing 
intravenous administration. These situations require other means of administering heroin as a 
substitute medication: oral substitution with diacetylmorphine has been used in Switzerland for a 
decade. Frick et al. demonstrated that the one year retention rate for solely orally-substituted 
subjects within the Swiss heroin-assisted treatment programs was 80%, which was above the 70% 
obtained from historical controls treated intravenously with diacetylmorphine (Frick et al., 2006). 
Diacetylmorphine is usually administered intravenously, but this may not be possible due to 
venosclerosis or when heroin abuse has occurred via non-intravenous routes (Nordt and Stohler, 
2006). Others want to reduce the health risks associated with drug administration (Frick et al., 
2006). In the Netherlands, administration by inhalation has been evaluated (Rook et al., 2006, Klous 
et al., 2005), and oral forms of diacetylmorphine have been developed in Switzerland within the 
heroin prescription program (HeGeBe = “Heroin Gestützte Behandlung”) conducted by the Swiss 
Federal Office of Public Health (Frick et al., 2006).  In 2006, one third of all diacetylmorphine used 
in the Swiss heroin prescription program this program was given as tablets (National Prevention 
Programmes of the Swiss Federal Office of Public Health, 2007). Furthermore, up to 25% of 
patients in this program receive diacetylmorphine doses orally (Bundesamt für Gesundheit, 2004) .  
It is often straightforward to characterise the absorption of oral immediate release 
preparations by model-independent estimation of bioavailability, maximal concentrations (Cmax), 
and time of maximal concentration (tmax). Alternatively, compartmental analysis may be used under 
the assumption of zero or first order absorption. For extended release preparations, analysis requires 
parameters describing the extent of fluctuation in plasma concentrations (Steinijans, 1990). 
Ignorance of the appropriate in vivo extended release absorption function often requires the use of 
deconvolution techniques (Fattinger and Verotta, 1995a, Fattinger and Verotta, 1995b, Fattinger et 
al., 2000, Pitsiu et al., 2001). This approach provides not only parameter estimates characterising 
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plasma level fluctuations, but also yields the entire drug absorption rate profile over time, allowing 
comparison of in vivo absorption rate with in vitro dissolution profiles (Pitsiu et al., 2001).  
We have shown previously that even large doses of oral immediate release diacetylmorphine 
yield only negligible systemic diacetylmorphine and monoacetylmorphine exposure, but result in an 
unexpectedly high morphine bioavailability of 67% (Girardin et al., 2003). Since many patients use 
extended release diacetylmorphine in addition to or instead of the immediate release form, often 
switching between formulations, we now characterise and compare morphine absorption of the two 
formulations in 8 opioid-addicted patients. For the extended release formulation, the study also 
explores the influence of a high-fat breakfast on morphine absorption.  
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2. Methods 
2.1.Materials 
Diacetylmorphine hydrochloride as immediate and extended release tablets of 200 mg were 
obtained from DiaMo Narcotics Ltd. (Thun, Switzerland). Deuterium-labelled morphine (morphine-
N-methyl-d3, morphine-d3) was obtained from Lipomed (Arlesheim, Switzerland) and doses for 
intravenous administration were prepared by the canton Zurich pharmacy (Kantonsapotheke Zürich, 
Switzerland). Diacetylmorphine, monoacetylmorphine, morphine, morphine-3-glucuronide, 
morphine-6-glucuronide, morphine-d3, morphine-d3-3-glucuronide, morphine-d3-6-glucuronide, 
and codeine-d3 used as assay standards were purchased from Lipomed (Arlesheim, Switzerland). 
 
2.2. Immediate and extended release diacetylmorphine preparation 
The immediate release preparation is a coated tablet with 200 mg diacetylmorphine 
hydrochloride as the active ingredient. At least 80% of the dose is released within 15 min 
(Conditions: Water, 37°C, Paddle 50 rpm). The immediate release preparation shows a fast 
disintegration within 300 s in water at 37°C.  In contrast, the extended release preparation is a 
coated matrix formulation, which releases the 200 mg of diacetylmorphine hydrochloride gradually 
over 12 h under the same conditions as above. The in vitro dissolution is specified with 20-40% 
release within 1 h, 45-65% within 4 h, and 80-100% within 10 h. Figure 1 shows the in vitro 
dissolution profiles of the two formulations. 
 
2.3. Clinical study  
The study protocol was approved by the ethics committee of the canton of Zürich. 
Volunteers requiring a stable daily parenteral and/or oral diacetylmorphine dose of at least a 300 mg 
parenteral dose equivalent were recruited from the HeGeBeSwiss heroin prescription programs. 
Parenteral dose equivalents were calculated by converting oral doses to parenteral doses by dividing 
them by 3three and summing them with parenteral doses. The morphine bioavailability of 67% 
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obtained in our previous study (Girardin et al., 2003) suggests that a lower conversion rate may be 
feasible. However, we again used the previously applied conversion rates (Girardin et al., 2003), 
since no signs of overdose were observed in the previous study (Girardin et al., 2003) and our main 
concern was withdrawal symptoms and the need for additional opioid delivery during the 7 or 11 h 
study sessions. Furthermore, oral, in contrast to intravenous, diacetylmorphine does not yield any 
systemic diacetylmorphine or monoacetylmorphine exposure. Moreover, morphine concentrations 
after oral diacetylmorphine rise more slowly and produce a subjective opioid effect that depends on 
the slope of the plasma concentration time curve. 
Potential volunteers were first contacted by their treating physician within the program and 
referred for further evaluation. Among 47 referred volunteers, 37 had to be excluded because of 
inaccessible veins (16), lack of cooperation (8), elevated transaminases (7), anaemia (3), 
concomitant medications (2), or impaired gastric emptying (1). Two further volunteers withdrew 
after the first study day. Written informed consent was obtained from all subjects prior to 
participation. A total of 8 volunteers, 4 women and 4 men, finished the study and were included in 
the analysis. All 8 volunteers were heavy smokers, with a mean age of 37 (28 to 50) years and a 
body weight of 62.3 (59 to 84.5) kg. Two volunteers reported occasional use of cannabis and 
another two of cocaine. On the first study day, urine drug testing for ethanol, cocaine, methadone, 
barbiturates, benzodiazepines, amphetamines, and lysergic acid diethylamide (LSD) were negative 
in all volunteers, but were positive for cannabis in two of them. All volunteers exhibited normal 
renal function and no signs of liver damage (i.e., normal plasma transaminases, bilirubin, INR, 
normal abdominal ultrasound examination, and negative hepatitis B and C serology). 
Volunteers had been opioid-dependent for 3 to 20 years and had participated in the HeGeBe 
for an average of 2.9 years (range: 4 weeks to 7 years). The mean daily parenteral diacetylmorphine 
dose equivalent amounted to 471 mg/d (300 to 867 mg/d). None of the volunteers took any 
additional medications for at least 3 days before or during the study. The oral diacetylmorphine 
doses for the study sessions were selected based on daily parenteral diacetylmorphine dose 
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equivalents. We wanted tTo ensure that volunteers would not be over-sedated or develop 
withdrawal and require additional opioids during the study sessions or receive excessive doses 
leading to adverse effects such as oversedation. Therefore, the immediate release diacetylmorphine 
doses were selected based on the algorithm used successfully during our last study, i.e. a single oral 
dose of amounted to 1.5-times the individual parenteral diacetylmorphine dose equivalent. 
Furthermore, and we limited the corresponding study sessions were limited to 7 h and allowed 
additional diacetylmorphine thereafter. To extend the study sessions to 11 h after administration of 
the extended release preparation, we increased doses in this case to 2 times the parenteral 
diacetylmorphine dose equivalent.  
After an overnight fast (i.e. no food or beverages except water after 11 pm), the volunteers 
arrived in the hospital at 7 AM and then stayed for 3 days at the Clinical Research Unit. A catheter 
was placed into the radial artery for blood sampling and into a vein of the other forearm for 
morphine-d3 administration. On the morning of the first study day, immediate release 
diacetylmorphine was administered orally with 100-200 ml of water. In addition, 15 mg of 
morphine-d3 dissolved in 30 ml NaCl was infused intravenously over 5 min starting immediately 
after the oral dose. Arterial blood samples (4.5 mL) were collected prior and 2.5, 5, 7.5, 10, 15, 20, 
25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 120, 180, 300 and 420 min after the oral diacetylmorphine 
dose. On one randomly selected morning of the second or third study day, the volunteers first ate a 
standardized (high fat content) breakfast consisting of 200 ml whole milk, 2 slices of toast, 20 g of 
butter, 55 g of Emmental cheese, one boiled egg, and 30 g of corn flakes (corresponding to 51 g of 
fat, 53 g of carbohydrates and 33 g of proteins). Thereafter, or on an empty stomach as on the first 
study day, the oral diacetylmorphine extended release dose was administered with 100-200 ml of 
water. Four subjects fasted on the second day and 4 were fed, and patients switched groups on the 
third day. Arterial blood samples were collected prior and 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, 
180, 210, 240, 270, 300, 360, 420, 480, 540 and 660 min after the diacetylmorphine dose. All blood 
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samples were collected directly into vials preloaded with sodium fluoride and centrifuged at 4 °C. 
The plasma was stored at –20 °C until analysis.  
Standardized meals were served on each day for lunch (4 h after the dose) and dinner. After 
the first hour, the volunteers were free to smoke cigarettes. During the period between the last blood 
sample and 10 PM, the volunteers received additional intravenous or oral immediate release 
diacetylmorphine (on average, 280 mg (day 1) and 230 mg (day 2 and 3) of parenteral dose 
equivalents) to maintain constant daily diacetylmorphine dosing.  
 
2.4. Determination of morphine, morphine-d3, and metabolite concentrations  
Plasma concentrations of diacetylmorphine, monoacetylmorphine, morphine, morphine-3-
glucuronide, morphine-6-glucuronide, morphine-d3, morphine-d3-3-glucuronide, and morphine-d3-
6-glucuronide were determined by liquid chromatography-mass spectrometry (LC-MS) with a 
quantification limit of 10 nmol/L as described previously (between-day precision < 9.5%, accuracy 
for all analytes between 97.4% and 103.7%) (Rentsch et al., 2001, Girardin et al., 2003).  
 
2.5. Non-compartmental pharmacokinetic analysis 
Individual morphine and glucuronide plasma half-life (t1/2) were calculated from the 
pharmacokinetic data after intravenous morphine administration as t1/2 = ln2/λ, where λ represents 
the slope of the terminal part of the plasma concentration-time curve after semi-logarithmic 
transformation. The areas under the plasma concentration-time curve (AUCs) were calculated as 
AUC(0-∝) = AUC(t0-tlast) + Clast / λ - C0 / λ, where tlast was the time of the last measurable plasma drug 
or metabolite concentration above the detection limit, Clast was the plasma drug or metabolite 
concentration of this last sample, and C0 was the plasma drug or metabolite concentration at the 
time of drug administration (t0). AUC(0-tlast) was calculated by the trapezoidal rule with linear 
interpolation.  
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Total plasma clearances were calculated from AUC and dose (D) for intravenous morphine-
d3 as CL = D/AUC. The volumes of distribution at steady state (Vss) were calculated as 
Vss = D * (AUMC) / (AUC)2, with AUMC being the total area under the first moment of the 
plasma concentration time curve (Gibaldi and Perrier, 1982). Absolute and relative bioavailability 
(F) were determined as F = (AUC1 / D1) / (AUC2 / D2), where AUC1, D1, AUC2 and D2 corresponds 
to AUC and dose for the oral diacetylmorphine versus the intravenous morphine-d3 dose, the oral 
extended versus immediate release dose, or the extended release dose administered in the fed and 
fasted state. To measure the fluctuation of plasma concentrations, we calculated the percent peak 
trough fluctuation (%PTF) as 100 * (Cmax - Cmin) / Cavg with Cavg = AUC0-11h / 11 h and the 
percent AUC fluctuation (%AUCF) as 100 * (AUC(above Cavg) + AUC(below Cavg) ) / AUC. 
(Steinijans, 1990). The geometric mean of absolute and relative bioavailabilities and other 
parameter estimates, as well as the corresponding confidence intervals, were then calculated.  
 
2.6. Deconvolution analysis 
If we view each subject as a linear, time-invariant system characterized by its morphine 
disposition function, K(t), we can relate the serum concentration response C(t) of that subject to an 
arbitrary morphine or diacetylmorphine dosage using a convolution of the absorption rate function, 
A(t), with the individual disposition function, K(t): 
∫ −= t jj dtKAtC
0
)()()( τττ  
The population (sample) average disposition function was estimated from the plasma 
concentration data collected after intravenous morphine-d3 administration using a standard two 
compartment model parameterised as k10, V1, k12, and k21, with interindividual variability on 
each parameter. A one-compartment model fitted the intravenous data considerably worse: we 
observed a difference in objective function (ΔOF) of 686 points, which is highly significant (the 
approximate 0.05% confidence level ΔOF is 3.9). No relevant improvement of the fit was achieved 
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with the inclusion of a third compartment. As a by-product of the (population) fit, the individual 
empirical Bayes estimates for the bi-exponential IV disposition functions were obtained. Drug 
absorption was described by a positively constrained linear (population) spline function for each 
study occasion, i.e. the administration of the immediate release dose, the extended release dose in 
the fasted state, and the extended release dose after a high-fat breakfast, and estimated from the data 
conditional on the individual bi-exponential disposition functions obtained from the intravenous 
morphine-d3 data analysis. The breakpoints of the spline were set at the quantiles of the data 
(Fattinger and Verotta, 1995a, Fattinger and Verotta, 1995b, Fattinger et al., 2000, Pitsiu et al., 
2001), and the spline(s) were parameterized to directly estimate absolute or relative bioavailabilities 
from the data of one or two study occasions combined (The corresponding NONMEM control 
stream and the data of two patients are given in Appendix 1). The 90% and 95% confidence 
intervals for the absolute or relative bioavailability estimates were obtained using a likelihood ratio 
profile (Bates and Watts, 1988).  
All calculations and drawings were done in Microsoft Excel and (S)-Plus 6.1 for Windows 
(Insightful Corporation, 2002) or with NONMEM VI under Windows or Unix (Beal and Sheiner, 
1992).  
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3. Results 
3.1.Adverse events 
All study doses were well tolerated. Only one adverse event was observed in which one 
volunteer requested one dose of paracetamol for a headache during the second night. 
Diacetylmorphine dosing was considered adequate on all study days.  
 
3.2. Non-compartmental pharmacokinetic analysis 
Intravenous morphine-d3: The AUC(0-∝) (mean ± SD) for morphine-d3, morphine-d3-3-
glucuronide, and morphine-d3-6-glucuronide was 30.7 ± 5.62, 250 ± 77, and 30 ± 9 min*μmol/l, 
respectively Morphine-d3 exhibited a clearance of 1.7 ± 0.3 l/min, a volume of distribution at 
steady state of 151 ± 42 l, and a terminal half-life of 1.74 ± 0.5 h. 
Oral immediate release diacetylmorphine: The diacetylmorphine dose (mean ± SD) was 719 
± 297 mg (1.77 ± 0.73 mmol). Similar to our previous study (Girardin et al., 2003), 
diacetylmorphine and monoacetylmorphine plasma concentrations were negligible. Morphine 
plasma concentrations peaked at 15 to 180 min, with maximal concentrations of 4.0 ± 1.27 μmol/l 
(Table 1, Figure 2A). The 7-h sampling period covered at least 80% of the morphine AUC. If we 
determine morphine bioavailability by comparing oral diacetylmorphine with intravenous 
morphine-d3, (absolute) morphine bioavailability was 61% ± 17% (range 44%-88%). The mean 
relative morphine-3-glucuronide and morphine-6-glucuronide bioavailabilities were 149% ± 64% 
and 184% ± 96%, respectively. 
Oral extended release diacetylmorphine: The mean extended release diacetylmorphine dose 
was 956 ± 404 mg (2.36 ± 1.0 mmol). Diacetylmorphine and monoacetylmorphine concentrations 
were again negligible. The 11-h sampling period covered at least 85% of the morphine AUC. 
Morphine bioavailability on an empty stomach was 53% ± 15% (range 37%-79%) (Table 1, Figure 
2B and C). Morphine bioavailability for extended release diacetylmorphine was lower in 4, higher 
in 3, and the same in 1 volunteer compared to immediate release diacetylmorphine. The geometric 
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mean relative bioavailability of morphine after extended vs. immediate release diacetylmorphine 
was 86% (90% CI, 73%-103%). Relative bioavailabilities for the morphine-glucuronides (81% and 
86%) were close to the values for morphine. A high-fat breakfast did not affect morphine 
bioavailability, yielding geometric mean relative bioavailabilities (fed/fasted) of 106%, 119%, and 
93% for morphine, morphine-3-glucuronide, and morphine-6-glucuronide. The relative fed vs. 
fasted morphine bioavailability has a rather narrow 90% confidence interval from 96% to 117%, 
which excludes any relevant food effect. 
Plasma concentration fluctuation was characterised by percent peak through fluctuation and 
percent AUC fluctuation. The peak-through fluctuation for the extended release preparation was 
about half that of the immediate release formulation (90% CI of 45% to 61%). The percent AUC 
fluctuation for the extended release formulation was only 0.66 (90% CI, 0.58 to 0.76) of the 
immediate release formulation. The presence of food did not increase either of these variability 
parameters. Maximal morphine concentrations were observed at 0.4 to 4.5 h in fasted and at 3 to 4.5 
h in fed conditions, with peak morphine concentrations of 2.98 ± 1.72 and 2.62 ± 1.06 μmol/l 
(Table 1, Figure 2B and C). Thus, dose-normalised maximal morphine plasma concentrations for 
extended release diacetylmorphine averaged about half of the immediate release diacetylmorphine, 
and were observed after about double the period of time.  
 
3.3. Deconvolution Analysis 
The three panels of Figure 3 compare data and the (population) prediction (solid line) for 
morphine plasma concentration after the immediate (A) and the extended release diacetylmorphine 
preparation in the fasted state (B) and after a high-fat breakfast (C). Panel A of Figure 4 compares 
the (population) morphine absorption rate profiles obtained from the deconvolution analysis. For 
the immediate release diacetylmorphine preparation, the morphine absorption rate rapidly peaks at 
about 10 to 15 min and more than 50% of the dose is absorbed after about 1.5 hours, with more than 
90% absorbed at 4.7 h. Morphine absorption was considerably slower and more sustained after 
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administration of the extended release diacetylmorphine preparation, with about 1/3 of the maximal 
absorption rate of the immediate release preparation observed from 10 min to 3.5 h after drug 
intake, with at least 50% of the dose absorbed after 3 hours and at least 90% absorbed after 8.5 h. 
Administration after a high-fat breakfast slightly delayed initial morphine absorption for about 20 to 
30 min, without much effect on later morphine absorption rates. 
The absolute and relative bioavailability estimates for the different preparations are given in 
Table 2, with point estimates of 0.57, 0.55 and 0.57 for immediate release, extended release in the 
fasted condition, and extended release after a high-fat breakfast. Panels B and C of Figure 4 
compare the estimated in vivo morphine absorption rate profile and the in vitro release rate profile 
for the extended release and the immediate release preparations. Absorption rate shortly after drug 
delivery rises considerably slower in vivo than was predicted by in vitro drug release, but the in vivo 
absorption rate – at least for the extended release formulation – subsequently catches up. 
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4. Discussion 
This study compared the morphine absorption characteristics of orally administered 
immediate and extended release diacetylmorphine in the high dose range required by opioid addicts. 
Both preparations exhibited a high mean absolute morphine bioavailability in the range of 56% to 
61%. The immediate release preparation resulted in rapid morphine absorption, with the absorption 
rate peaking at 10 to 15 min after dosing. For the extended release formulation, morphine 
absorption rates were considerably lower and more sustained, with only about 30% of the maximal 
absorption rate (of the immediate release preparation) being reached after 10 min and then 
maintained for 3 to 4 h, with no relevant food interaction. The relative bioavailability of the two 
preparations was 86% for the non-compartmental or 93% for the deconvolution analysis. Therefore, 
it can be concluded that these two diacetylmorphine preparations produce the intended morphine 
exposures and are suitable for substitution with similar dosages when given sequentially or in 
combination to the same patient. The part of the dose given as an immediate release formulation 
will assure a rapid opioid effect, whereas the part given in an extended release form maintains 
opioid availability until the patient’s next visit to the treatment center.  
The rapid absorption and concentration rise of the immediate release preparation is 
advantageous, since the pharmacodynamic effects of opioids depend on both the substance and the 
initial slope of the plasma concentration. Two factors probably contribute to the rapid initial rise in 
drug absorption: diacetylmorphine produces a more rapid rise in morphine levels than oral 
morphine (Girardin et al., 2003) and a pharmaceutical formulation designed for rapid disintegration 
of the tablets. Based on this absorption rate profile, a rapidly disintegrating immediate release 
formulation might be especially suited for addicted patients that used opioids parenterally, by 
inhalation, or nasally.  
The extended release diacetylmorphine preparation produces a lower but more sustained 
morphine exposure, which could avoid a drug-related “high”. Morphine absorption reached 90% 
only after 8.5 hours, allowing for an extended dosing interval that could improve compliance, as 
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dosing requires scheduled visits to treatment centres. Flexible dosing can also be achieved as food 
does not affect drug absorption. Clinically, these findings confirm the indications of extended 
release diacetylmorphine, which are recommended for situations requiring the absence of a drug 
“high,” such as working patients, or in patients preparing for diacetylmorphine withdrawal. 
Furthermore, the extended release preparation allows for prolonged dosing intervals and thus 
enhances the ability for employment.  
In vivo absorption profiles differ clearly from the in vitro dissolution profile for both the 
immediate and the extended release preparations (Figure 4B and 4C). Similar differences also occur 
with the slow release oxybutynin OROS (Pitsiu et al., 2001), stressing the importance of in vivo 
studies even for drugs with high water or lipid solubility, such as diacetylmorphine. 
Deconvolution analysis enabled us to characterise and visually compare the time courses of 
drug absorption for the different preparations, and to compare them to the in vitro dissolution 
profiles, as well as calculating absolute and relative bioavailability. Most parameter estimates and 
confidence intervals matched closely in both data analysis approaches, i.e. the standard AUC 
calculation and the deconvolution approach. In deconvolution analysis, the 90% confidence interval 
for the relative bioavailability of the extended release preparation was more narrow (80.5% to 
107.2%) than AUC calculations (73.1% to 105.0%), suggesting that deconvolution analysis may be 
more robust with respect to outliers. The reason for the observed (but probably clinically irrelevant) 
differences in the point bioavailability estimates of 61% vs. 57% (immediate release) and 53% vs. 
55% (extended release) for the two data analysis approaches remains unresolved.  
The slightly lower bioavailability of extended as compared to immediate release 
diacetylmorphine could result from lower maximal concentrations leading to more efficient first 
pass elimination in the intestine and liver, or lower mucosal diacetylmorphine and/or morphine 
permeability in the distal than the proximal intestine.  
In conclusion, orally administered immediate and extended release diacetylmorphine both 
exhibit a high absolute morphine bioavailability of 56% to 61% in the dose range required by opioid 
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addicts. The immediate release preparation produces rapid morphine absorption, whereas 
absorption rates are considerably lower and more sustained for the extended release formulation, 
with 90% of morphine absorption reached only after 8.5 h, which would allow for extending dosing 
intervals. Morphine absorption was not significantly affected by a high-fat breakfast. The relative 
bioavailability of the two preparations was 86% (non-compartmental analysis) or 93% 
(deconvulution analsyis), indicating they can be substituted for each other with a one to one ratio. 
The absorption characteristics could improve outcomes in patients switching from parenteral 
opioids or for well-integrated patients under chronic treatment to enhance employability. 
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 Tables 
Table 1: Pharmacokinetic comparison of oral immediate (IR) and extended (ER) release 
diacetylmorphine. 
 Parameter Estimate a Ratio b 
Formulation  IR ER ER ER / IR ER / ER 
Condition fasted fasted fed fasted fed / fasted 
Dose (D, mmol) 1.77 ± 0.73 2.36 ± 1.00 2.36 ± 1.00 --- 1 
Morphine      
Cmax.(µmol/L) 4.00 ± 1.27 2.98 ± 1.72 2.62 ± 1.06 --- --- 
Cmax / D (10-3/L) 2.42 ± 0.88 1.23 ± 0.47 1.14 ± 0.22 
0.51 
(0.41, 0.63) 
0.97 
(0.81, 1.15) 
Cmin.(µmol/L) c  0.11 ± 0.12 0.44 ± 0.24 0.50 ± 0.31 --- --- 
Cmin / D (10-3/L) 0.05 ± 0.05 0.18 ± 0.06 0.20 ± 0.09 
4.9            
(3.1, 7.7) 
1.04         
(0.87, 1.25) 
tmax (min) 76 ± 52 157 ± 71 263 ± 33 
2.29 
(1.62, 3.24) 
1.96 
(1.32, 2.93) 
AUC0-∝ (mmol*min/L) 0.63 ± 0.29 0.72 ± 0.32 0.76 ± 0.33 --- --- 
F (%) d 61 ± 17 53 ± 15 56 ± 15 86 (73.1, 105) 
106 
(96, 117) 
%PTF f  450 ± 227 235 ± 122 202 ± 78 0.52 (0.45, 0.61) 
0.89 
(0.70, 1.13) 
%AUCF g 0.664 ± 0.233 0.428 ± 0.104 0.428 ± 0.127 0.66 (0.58, 0.76) 
0.99 
(0.85, 1.14) 
Morphine-3-glucuronide 
AUC0-∝ (mmol*min/L) 11.1 ± 4.5 12.9 ± 7.3 14.6 ± 6.0 --- --- 
AUC0-∝ / D (min/L) 6.68 ± 2.31 5.51 ± 2.08 6.42 ± 2.30 --- --- 
F rel (%) e 149 ± 64 --- --- 
81 
(58, 113) 
119 
(100, 142) 
Morphine-6-glucuronide 
AUC0-∝ (mmol*min/L) 1.7 ± 1.0 1.9 ± 1.0 1.8 ± 0.8 --- --- 
AUC0-∝ / D (min/L) 1.02 ± 0.50 0.81 ± 0.22 0.75 ± 0.18 --- --- 
F rel (%) d 184 ± 96 --- --- 
86 
(63, 119) 
93 
(79, 110) 
a Values are given as mean ± SD 
b Values are given as geometric mean and 90% confidence interval 
c  For the extended release preparation, Cmin corresponds to the minimal concentration observed after Cmax during the 11 h sampling 
period, and for the immediate release preparation to the extrapolated concentration at 11 h after drug administration 
d Morphine bioavailability was determined by comparing dose-normalized morphine AUCs after oral diacetylmorphine and 
intravenous morphine-d3 administration. 
e Relative morphine-glucuronide bioavailabilities were determined by comparing dose- normalized morphine-glucuronide AUCs 
from oral diacetylmorphine and intravenous morphine-d3 administration. 
f     %PTF percent peak trough fluctuation, i.e. 100 * (Cmax-Cmin) / Cavg with Cavg = AUC0-11h / 11h  
g      %AUCF percent AUC fluctuation, i.e. 100 * (AUC(above Cavg) + AUC(below Cavg) ) / AUC 
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Table 2: Absolute and relative bioavailability estimates for immediate (IR) and extended release 
(ER) diacetylmorphine from the deconvolution analysis in NONMEM and their 90% and 95% 
confidence intervals. 
 Point estimate 90% CI a 95% CI a 
IR 0.57 (0.49, 0.65) (0.48, 0.67) 
ER fasted 0.55 (0.50, 0.59) (0.50, 0.59) 
ER with food 0.57 (0.53, 0.62) (0.53, 0.62) 
ER vs. IR 0.93 (0.805, 1.072) (0.783, 1.100) 
ER with food vs. fasted 1.08 (0.988, 1.192) (0.971, 1.211) 
a  90% and 95% confidence intervals are based on a likelihood ratio profiles. 
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Figure Legends 
Figure 1: In vitro diacetylmorphine dissolution profiles of immediate and extended release 
tablets: Six single tablets of immediate (IR) or extended release (ER) diacetylmorphine were 
subjected to dissolution profiling with a standard USP dissolution apparatus. Values are given as 
mean ± standard deviations. 
 
Figure 2: Individual morphine plasma concentration–time profiles after orally administered 
immediate (A) and extended release diacetylmorphine in the fasted (B) and the fed (C) state. 
Solid lines connect measured plasma concentrations, dashed lines correspond to plasma 
concentration extrapolations based on the last sample (at 7 h) and the subject’s terminal morphine 
elimination rate estimated from the intravenous morphine-d3. Identical symbols are used for the 
same patient in all 3 panels. The mean diacetylmorphine doses were 719 mg (1.77 mmol) for 
immediate and 956 mg (2.36 mmol) for extended release diacetylmorphine. 
 
Figure 3: Goodness-of-fit plots for immediate (A) and extended release diacetylmorphine in the 
fasted (B) and the fed (C) state from deconvolution analysis using a bi-exponential disposition 
and a linear spline absorption function. The (X) represents the observed data and the solid lines 
correspond to the average predictions. 
 
Figure 4: Population morphine absorption rate function for immediate (dashed-dotted line) 
and extended release diacetylmorphine in the fasted (solid line) and the fed (short dashed line) 
state estimated by deconvolution analysis using a bi-exponential disposition and a linear 
spline absorption function. Panel A gives the estimated absorption rate functions obtained by 
deconvolution analysis for the oral immediate and extended release diacetylmorphine preparation. 
Panel B and C compare the morphine absorption rate functions obtained by deconvolution analysis 
from the drug concentration data and the corresponding diacetylmorphine release profiles from the 
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in vitro experiments (long dashed line) for the extended release (B) and the immediate (C) 
preparations.  
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Appendix 1 
Example of a NONMEM control stream used in the deconvolution analysis 
 
$PROBLEM DAM absorption - estimate input function for SR using a linear spline in B-spline representation  
$INPUT XID DV DMOL TIME EVID RATE DOSE=AMT SS CMT ET1 ET2 ET3 ET4 
$DATA Datapape IGNORE=#  
 
$SUBROUTINES  ADVAN6  TOL=5 
 
$MODEL 
COMP=(CENTRAL,DEFDOSE) 
COMP=(PERIPH)  
 
$PK 
; 2 cmp disposition model: population (THn) individual (ETn, obtained from data) pk parameters from disposition analysis 
; the system ist set to steady state with the first data record of each individual at his/her measured Co 
TH1=8.50 
TH2=12.5 
TH3=10.8 
TH4=0.847 
K10 = TH1*EXP(ET1)  
V1= TH2*EXP(ET2) 
K12 = TH3*EXP(ET3) 
K21 = TH4*EXP(ET4) 
S1 = V1 
 
$DES  
 
; define breakpoints BDES 1 to 7 at the quatiles of the time data  
BDES1=0.0 
BDES2=0.2361667 
BDES3=0.639 
BDES4=1.1665 
BDES5=3.166667 
BDES6=5.166667  
BDES7=11  
 
; reset basis values to zero 
BDESV1=0 
BDESV2=0 
BDESV3=0 
BDESV4=0 
BDESV5=0 
BDESV6=0 
BDESV7=0 
 
 
IDES=0  
 
IF (T.GE.BDES1.AND.T.LT.BDES2) BDESV1=THETA(1)*(BDES2-T)/(BDES2-BDES1)  
IF (T.GE.BDES1.AND.T.LT.BDES2) BDESV2=THETA(2)*(T-BDES1)/(BDES2-BDES1) 
IF (T.GE.BDES2.AND.T.LT.BDES3) BDESV2=THETA(2)*(BDES3-T)/(BDES3-BDES2)  
IF (T.GE.BDES2.AND.T.LT.BDES3) BDESV3=THETA(3)*(T-BDES2)/(BDES3-BDES2) 
IF (T.GE.BDES3.AND.T.LT.BDES4) BDESV3=THETA(3)*(BDES4-T)/(BDES4-BDES3)  
IF (T.GE.BDES3.AND.T.LT.BDES4) BDESV4=THETA(4)*(T-BDES3)/(BDES4-BDES3) 
IF (T.GE.BDES4.AND.T.LT.BDES5) BDESV4=THETA(4)*(BDES5-T)/(BDES5-BDES4)  
IF (T.GE.BDES4.AND.T.LT.BDES5) BDESV5=THETA(5)*(T-BDES4)/(BDES5-BDES4) 
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IF (T.GE.BDES5.AND.T.LT.BDES6) BDESV5=THETA(5)*(BDES6-T)/(BDES6-BDES5)  
IF (T.GE.BDES5.AND.T.LT.BDES6) BDESV6=THETA(6)*(T-BDES5)/(BDES6-BDES5)  
IF (T.GE.BDES6.AND.T.LE.BDES7) BDESV6=THETA(6)*(BDES7-T)/(BDES7-BDES6)  
IF (T.GE.BDES6.AND.T.LE.BDES7) BDESV7=THETA(7)*(T-BDES6)/(BDES7-BDES6)  
 
 
A1= THETA(1)*(BDES2-BDES1)/2 
A2= THETA(2)*(BDES3-BDES1)/2 
A3= THETA(3)*(BDES4-BDES2)/2 
A4= THETA(4)*(BDES5-BDES3)/2 
A5= THETA(5)*(BDES6-BDES4)/2 
A6= THETA(6)*(BDES7-BDES5)/2 
A7= THETA(7)*(BDES7-BDES6)/2 
 
AREA=A1+A2+A3+A4+A5+A6+A7 
 
BIO=THETA(8) 
 
IDES = DMOL/AREA * BIO * 1000 * (BDESV1+BDESV2+BDESV3+BDESV4+BDESV5+BDESV6+BDESV7) 
 
DADT(1)=K21*A(2)-A(1)*(K10+K12)+IDES 
DADT(2)=K12*A(1)-K21*A(2)  
 
$ERROR 
Y=F*EXP(ERR(1))  
 
$THETA 
(0 0.01) 
(0 0.02) 
(0 0.05) 
(1 FIXED) ; fix one theta (expected not to go to 0) to 1 so that we have 1 parameter left to estimate bioavailability  
(0 0.03) 
(0 0.05) 
(0 0.01) 
 
(0 0.6)    ; bioavailability 
 
$OMEGA .3 
 
$EST  
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Example of af the corresponding data set (first two patients) 
# I    DV    Dmol    Time     EVID    RATE       AMT   SS   CMT   ET1       ET2       ET3        ET4 
   3     .   1601    0.0000      4   43730         0    1     1  1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    330  1601    0.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    795  1601    0.1667      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    985  1601    0.3333      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1075  1601    0.5000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1060  1601    0.6667      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1105  1601    0.8333      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1028  1601    1.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1260  1601    1.3333      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1753  1601    1.6667      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1994  1601    2.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1243  1601    2.5000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1338  1601    3.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1301  1601    3.5000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    990  1601    4.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    941  1601    4.5000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3   1023  1601    5.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    795  1601    6.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    615  1601    7.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    510  1601    8.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    384  1601    9.0000      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   3    289  1601   11.2583      0      .         .    .     .   1.62E-01  5.89E-02  -8.78E-02  5.07E-01 
   4     .   1971    0.0000      4   41838         0    1     1  2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    404  1971    0.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    426  1971    0.1667      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    655  1971    0.3333      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    696  1971    0.5000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    922  1971    0.6667      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    425  1971    0.8458      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    593  1971    1.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    765  1971    1.3333      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   1573  1971    1.6667      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   4493  1971    2.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   1788  1971    2.5000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   1179  1971    3.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   1002  1971    3.5000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   1123  1971    4.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4   1034  1971    4.5000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    842  1971    5.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    706  1971    6.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    431  1971    7.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    401  1971    8.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    293  1971    9.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
   4    269  1971   11.0000      0      .         .    .     .   2.02E-01 -2.28E-01  -7.39E-02  1.54E-01 
